|
Objective : Diabetic nephropathy as a complication of diabetes , in the event , often showed irreversible progress in the eventual development of renal failure, can only rely on dialysis or kidney transplantation to sustain life , to patients with tremendous physical and mental suffering and economic burden. Therefore, how effective prevention and treatment of diabetic nephropathy become the focus of attention of many scholars . Fenofibrate is a phenoxy acid lowering drugs , widely used in the treatment of hyperlipidemia . In recent years, found that lipid-lowering effect of fenofibrate in addition to outside , there are anti-inflammatory effect, affecting coagulation - fibrinolysis system , fight insulin resistance and so on. In the study of fenofibrate on the prevention and treatment of atherosclerosis , it was found that it can activate PPAR-α receptor and inhibit NF-κB activity, thus reducing vascular cell adhesion molecule -1 (VCAM-1), IL-6 , CRP expression through anti -inflammatory mechanisms play a role in atherosclerosis . Recent studies showed that the development of diabetic nephropathy in the process of inflammation involved , NF-κB its key . Animal and clinical experiments confirmed that peripheral blood mononuclear cells of diabetic nephropathy and renal tissue NF-κB activity increased , and to MCP-1 gene expression, which makes monocyte chemoattractant to promote inflammation in the form of progression of diabetic nephropathy . Recent studies have shown that lipid-lowering effects of fenofibrate can make diabetic rats reduced the expression of TGF-β1 play on diabetic nephropathy in rats. This test is intended to establish diabetic rats SD rats , treatment with fenofibrate , immunohistochemical determination of NF-κB, MCP-1 expression studies fenofibrate renal protection mechanism and with NF-κB, MCP-1 in relation to the clinical treatment of diabetic nephropathy provide theoretical guidance . Methods: Healthy male SD rats of clean grade 36 , weight
|